The reiteration of an Overweight rating by a major financial institution like Wells Fargo suggests a bullish stance on Avidity Biosciences, which could instill confidence in investors and positively influence the stock's short-term performance. The maintenance of a $50 price target indicates that the analyst believes the stock has the potential to reach or exceed this value, further supporting a positive short-term impact.